Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
MELBOURNE, Australia, Oct. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix...
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
MELBOURNE, Australia, Oct. 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®[1]), an agent for the imaging of g...
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
MELBOURNE, Australia, Oct. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma[1], which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two gen...
Telix Files Form 20-F Registration Statement for Nasdaq ADS
MELBOURNE, Australia, Oct. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registration Statement) withthe United States (U.S.) Securities and Exchange Commission (SEC) relating to a pro...
Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
MELBOURNE, Australia, Oct. 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended30 September 2024 (Q3 2024). Revenue update, full year guidance reaffirmed * Unaudited to...
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of68Ga-PSMA-11[1] injection) to select patients for...
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentu...
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
MELBOURNE, Australia, INDIANAPOLIS and LAKE MARY, Fla., Sept. 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and th...
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
MELBOURNE, Australia, Sept. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET[1] ag...
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET[2] agent,...
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published inNeuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 thera...
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
MELBOURNE, Australia, Aug. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) tothe United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET)...
Telix Announces Reorganisation to Deliver on Strategic Priorities
MELBOURNE, Australia, Aug. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiop...
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
MELBOURNE, Australia, Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended30 June 2024. All figures are in AU$ unless otherwise stated.[1] H1 2024 financial highlights * Total Group revenue o...
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold ki...
Telix Successfully Prices A$650 Million Convertible Bonds
MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully pricedA$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bond...
Telix Announces A$600 Million Convertible Bonds Offering
MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...
Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade
MELBOURNE, Australia, July 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended30 June 2024 (Q2 2024). Q2 2024 Financial Performance and Guidance Upgrade The Company rep...
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
MELBOURNE, Australia, July 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective Payment System (OPPS) rule to improve payments ...
Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) tothe United States (U.S.) Food and Drug Administration (FDA) for its investigational radi...
